News Briefs: CMS Will Hold Events for Drug Price Negotiation in April 2025
-
Mar 13, 2025
CMS revealed its public engagement events for the second round of Medicare drug price negotiations on Feb. 21. The agency will hold two livestreamed town halls for all selected drugs on April 30, as well as 15 private patient-focused roundtables, one for each drug and organized alphabetically, from April 16 through April 29.
ImmunityBio, Inc. said on Feb. 19 that the FDA has authorized it to provide next-generation recombinant Bacillus Calmette-Guerin (rBCG) to the U.S. via an expanded access program to treat people with bladder cancer. The agent, which has been developed by the Serum Institute of India, has undergone Phase II clinical trials in Europe for the treatment of non-muscle invasive bladder cancer (NMIBC). BCG has been the standard of care for people with NMIBC since 1977, but it has been in short supply for several years. Merck & Co., Inc. became the sole supplier of BCG in the U.S. in 2012, and the current shortage began in 2019, when the company began allocating the available supply. Merck has said it is constructing a new manufacturing facility in Durham, North Carolina, to expand its production capacity for BCG.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.